•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.$HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger — BWMN, UTZ , PASG and FNWD
MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD
Passage Bio, Inc. (NASDAQ:PASG) Stock Has Average Price Target of $13.25 According to Brokerages
Passage Bio (NASDAQ:PASG) Stock Falls 2.4% – Here’s What Happened
Analysts Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $13.25
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio and Remix Therapeutics Announce Merger Agreement
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights